Phenotypes of prediabetes and stratification of cardiometabolic risk

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 9, 2016, Pages 789-798

  Stefan, Norbert ^a,b,c   Fritsche, Andreas ^a,b,c   Schick, Fritz ^a,b,c   Häring, Hans Ulrich ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; NATEGLINIDE; PIOGLITAZONE;

CARDIOMETABOLIC RISK; DIETARY INTAKE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; ABDOMINAL OBESITY; COMPLICATION; METABOLISM; RISK ASSESSMENT; SECRETION (PROCESS);

HUMANS; INSULIN; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, ABDOMINAL; PHENOTYPE; PREDIABETIC STATE; RISK ASSESSMENT;

EID: 84967195426     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)00082-6     Document Type: Review

References (95)

1. 1 GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 2287–2323.
2. 2 Menke, A, Casagrande, S, Geiss, L, Cowie, CC, Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314 (2015), 1021–1029.
3. 3 Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE, Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
4. 4 Chan, JC, Zhang, Y, Ning, G, Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol 2 (2014), 969–979.
5. 5 Huo, X, Gao, L, Guo, L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4 (2016), 115–124.
6. 6 Zimmet, PZ, Magliano, DJ, Herman, WH, Shaw, JE, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2 (2014), 56–64.
7. 7 Seshasai, SR, Kaptoge, S, Thompson, A, et al., for the Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
8. 8 American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 39:suppl (2016), S13–S22.
9. 9 Ferrannini, E, Definition of intervention points in prediabetes. Lancet Diabetes Endocrinol 2 (2014), 667–675.
10. 10 Tabák, AG, Herder, C, Rathmann, W, Brunner, EJ, Kivimäki, M, Prediabetes: a high-risk state for diabetes development. Lancet 379 (2012), 2279–2290.
11. 11 Kahn, SE, Cooper, ME, Del Prato, S, Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383 (2014), 1068–1083.
12. 12 Laakso, M, Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33 (2010), 442–449.
13. 13 Defronzo, RA, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
14. 14 Stancáková, A, Javorský, M, Kuulasmaa, T, Haffner, SM, Kuusisto, J, Laakso, M, Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58 (2009), 1212–1221.
15. 15 Lyssenko, V, Jonsson, A, Almgren, P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359 (2008), 2220–2232.
16. 16 Laakso, M, Zilinskaite, J, Hansen, T, et al., for the EUGENE2 Consortium. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51 (2008), 502–511.
17. 17 Weyer, C, Bogardus, C, Mott, DM, Pratley, RE, The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999), 787–794.
18. 18 Gerstein, HC, Santaguida, P, Raina, P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 78 (2007), 305–312.
19. 19 Knowler, WC, Fowler, SE, Hamman, RF, et al., for the Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374 (2009), 1677–1686.
20. 20 Ferrannini, E, Massari, M, Nannipieri, M, et al. Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. Diabetologia 52 (2009), 818–824.
21. 21 Ligthart, S, van Herpt, TT, Leening, MJ, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4 (2016), 44–51.
22. 22 Abdul-Ghani, MA, Lyssenko, V, Tuomi, T, DeFronzo, RA, Groop, L, Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32 (2009), 281–286.
23. 23 Faerch, K, Hulmán, A, Solomon, TP, Heterogeneity of pre-diabetes and type 2 diabetes: implications for prediction, prevention and treatment responsiveness. Curr Diabetes Rev 12 (2016), 30–41.
24. 24 Faerch, K, Vaag, A, Holst, JJ, Hansen, T, Jørgensen, T, Borch-Johnsen, K, Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32 (2009), 439–444.
25. 25 Faerch, K, Witte, DR, Tabák, AG, et al. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol 1 (2013), 43–51.
26. 26 Faerch, K, Johansen, NB, Witte, DR, Lauritzen, T, Jørgensen, ME, Vistisen, D, Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab 100 (2015), 707–716.
27. 27 Mooy, JM, Grootenhuis, PA, de Vries, H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39 (1996), 298–305.
28. 28 The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 311 (2014), 1225–1233.
29. 29 Gilbert, RE, Mann, JF, Hanefeld, M, et al., for the ORIGIN trial investigators. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 57 (2014), 1325–1331.
30. 30 Lonn, EM, Bosch, J, Diaz, R, et al., for the GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 36 (2013), 2466–2474.
31. 31 Gerstein, HC, Bosch, J, Dagenais, GR, et al., for the ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
32. 32 Cukierman-Yaffe, T, Bosch, J, Diaz, R, et al., for the ORIGIN Investigators. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2 (2014), 562–572.
33. 33 Saltiel, AR, Kahn, CR, Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
34. 34 Nerpin, E, Risérus, U, Ingelsson, E, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 31 (2008), 1550–1555.
35. 35 Hotamisligil, GS, Inflammation and metabolic disorders. Nature 444 (2006), 860–867.
36. 36 Osborn, O, Olefsky, JM, The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18 (2012), 363–374.
37. 37 Rosen, ED, Spiegelman, BM, What we talk about when we talk about fat. Cell 156 (2014), 20–44.
38. 38 Shulman, GI, Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371 (2014), 2237–2238.
39. 39 Tuligenga, RH, Dugravot, A, Tabák, AG, et al. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol 2 (2014), 228–235.
40. 40 Rawlings, AM, Sharrett, AR, Schneider, AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 161 (2014), 785–793.
41. 41 Crane, PK, Walker, R, Hubbard, RA, et al. Glucose levels and risk of dementia. N Engl J Med 369 (2013), 540–548.
42. 42 Baker, LD, Cross, DJ, Minoshima, S, Belongia, D, Watson, GS, Craft, S, Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68 (2011), 51–57.
43. 43 Xu, W, Caracciolo, B, Wang, HX, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59 (2010), 2928–2935.
44. 44 LeRoith, D, Yakar, S, Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 3 (2007), 302–310.
45. 45 Pollak, M, The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12 (2012), 159–169.
46. 46 Liao, WC, Tu, YK, Wu, MS, Lin, JT, Wang, HP, Chien, KL, Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ, 349, 2015, g7371.
47. 47 Huang, Y, Cai, X, Qiu, M, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57 (2014), 2261–2269.
48. 48 Herder, C, Dalmas, E, Böni-Schnetzler, M, Donath, MY, The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 26 (2015), 551–563.
49. 49 DeFronzo, RA, Eldor, R, Abdul-Ghani, M, Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 36:suppl 2 (2013), S127–S138.
50. 50 DeFronzo, RA, Tripathy, D, Schwenke, DC, et al., for the ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364 (2011), 1104–1115.
51. 51 Holman, RR, Haffner, SM, McMurray, JJ, et al., for the NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1463–1476.
52. 52 Eizirik, DL, Cnop, M, ER stress in pancreatic β cells: the thin red line between adaptation and failure. Sci Signal, 3, 2010, pe7.
53. 53 Tuomilehto, J, Lindström, J, Eriksson, JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001), 1343–1350.
54. 54 Lindström, J, Ilanne-Parikka, P, Peltonen, M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006), 1673–1679.
55. 55 Knowler, WC, Barrett-Connor, E, Fowler, SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
56. 56 Pan, XR, Li, GW, Hu, YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997), 537–544.
57. 57 Li, G, Zhang, P, Wang, J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371 (2008), 1783–1789.
58. 58 Li, G, Zhang, P, Wang, J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2 (2014), 474–480.
59. 59 Artinian, NT, Fletcher, GF, Mozaffarian, D, et al., for the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 122 (2010), 406–441.
60. 60 Lindström, J, Peltonen, M, Eriksson, JG, et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 31 (2008), 857–862.
61. 61 Perreault, L, Pan, Q, Mather, KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379 (2012), 2243–2251.
62. 62 Perreault, L, Kahn, SE, Christophi, CA, Knowler, WC, Hamman, RF, for the Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 32 (2009), 1583–1588.
63. 63 Lillioja, S, Mott, DM, Spraul, M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329 (1993), 1988–1992.
64. 64 Tabák, AG, Jokela, M, Akbaraly, TN, Brunner, EJ, Kivimäki, M, Witte, DR, Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373 (2009), 2215–2221.
65. 65 Ohn, JH, Kwak, SH, Cho, YM, et al. 10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabetes Endocrinol 4 (2016), 27–34.
66. 66 Neeland, IJ, Turer, AT, Ayers, CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 308 (2012), 1150–1159.
67. 67 Zelber-Sagi, S, Lotan, R, Shibolet, O, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 33 (2013), 1406–1412.
68. 68 Stefan, N, Staiger, H, Wagner, R, et al. A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 58 (2015), 2877–2884.
69. 69 Stefan, N, Häring, HU, The metabolically benign and malignant fatty liver. Diabetes 60 (2011), 2011–2017.
70. 70 Stefan, N, Kantartzis, K, Machann, J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168 (2008), 1609–1616.
71. 71 Stefan, N, Ramsauer, M, Jordan, P, et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 406–416.
72. 72 Stefan, N, Häring, HU, Hu, FB, Schulze, MB, Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1 (2013), 152–162.
73. 73 Wildman, RP, Muntner, P, Reynolds, K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168 (2008), 1617–1624.
74. 74 McLaughlin, T, Abbasi, F, Lamendola, C, Reaven, G, Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 167 (2007), 642–648.
75. 75 Karelis, AD, St-Pierre, DH, Conus, F, Rabasa-Lhoret, R, Poehlman, ET, Metabolic and body composition factors in subgroups of obesity: what do we know?. J Clin Endocrinol Metab 89 (2004), 2569–2575.
76. 76 Samocha-Bonet, D, Dixit, VD, Kahn, CR, et al. Metabolically healthy and unhealthy obese—the 2013 Stock Conference report. Obes Rev 15 (2014), 697–708.
77. 77 Lotta, LA, Abbasi, A, Sharp, SJ, et al. Definitions of metabolic health and risk of future type 2 diabetes in BMI categories: a systematic review and network meta-analysis. Diabetes Care 38 (2015), 2177–2187.
78. 78 Mathew, H, Farr, OM, Mantzoros, CS, Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 65 (2016), 73–80.
79. 79 Stefan, N, Kantartzis, K, Häring, HU, Causes and metabolic consequences of Fatty liver. Endocr Rev 29 (2008), 939–960.
80. 80 Targher, G, Day, CP, Bonora, E, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
81. 81 Cusi, K, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 142, 2012, 711 25.e6.
82. 82 Yki-Järvinen, H, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
83. 83 Calori, G, Lattuada, G, Piemonti, L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 34 (2011), 210–215.
84. 84 Kramer, CK, Zinman, B, Retnakaran, R, Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 159 (2013), 758–769.
85. 85 Bell, JA, Hamer, M, Sabia, S, Singh-Manoux, A, Batty, GD, Kivimaki, M, The natural course of healthy obesity over 20 years. J Am Coll Cardiol 65 (2015), 101–102.
86. 86 Appleton, SL, Seaborn, CJ, Visvanathan, R, et al., for the North West Adelaide Health Study Team. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 36 (2013), 2388–2394.
87. 87 Bell, JA, Hamer, M, Batty, GD, Singh-Manoux, A, Sabia, S, Kivimäki, M, Incidence of metabolic risk factors among healthy obese adults: 20-year follow-up. J Am Coll Cardiol 66 (2015), 871–873.
88. 88 Turer, AT, Scherer, PE, Adiponectin: mechanistic insights and clinical implications. Diabetologia 55 (2012), 2319–2326.
89. 89 Blüher, M, Are metabolically healthy obese individuals really healthy?. Eur J Endocrinol 171 (2014), R209–R219.
90. 90 Stefan, N, Häring, HU, The role of hepatokines in metabolism. Nat Rev Endocrinol 9 (2013), 144–152.
91. 91 Stefan, N, Häring, HU, Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med, 19, 2013, 39495.
92. 92 Stefan, N, Schick, F, Häring, HU, Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371 (2014), 2236–2237.
93. 93 Scott, RA, Fall, T, Pasko, D, et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes 63 (2014), 4378–4387.
94. 94 Ingelsson, E, Langenberg, C, Hivert, MF, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes 59 (2010), 1266–1275.
95. 95 Schwenzer, NF, Springer, F, Schraml, C, Stefan, N, Machann, J, Schick, F, Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51 (2009), 433–445.